American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
November 13, 2023
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Jason, and I appreciate all of you being with us today. Our earnings press release for AMS' third quarter of 2023 came out this afternoon at 4:01 p.m. Eastern Time. Should you require a copy, you'll find it on the company's website, ashs.com, under the Investors tab at Press Releases. Before I hand things over to management, I want to share a few remarks regarding forward-looking statements. Please be aware that any comments made during this conference call regarding future expectations, plans, and prospects for the company are considered forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, due to a number of important factors, such as those covered in the company's SEC filings; among these are the company's quarterly report on Form 10-Q for the 3-month period ended March 31 and June 30, 2023, the annual report on Form 10-K for the year ended December 31, 2022, and the definitive proxy statement for the Annual Meeting of Shareholders held on June 20, 2023. The company undertakes no obligation to update the information in this conference call. Before handing the call to Ray, I want to let everyone know that starting with this quarter's call, we're putting a new Q&A policy in place. We're asking that all participants restrict themselves to one question plus one follow-up. As always, we're glad to address any further questions offline whenever you like. With that, I'll now hand the call over to Ray Stachowiak, Executive Chairman. Ray?
Ray Stachowiak
executiveThanks, Stephanie, and good afternoon, everyone. We’re glad you could join us for this conference call covering our results for 2023’s third quarter. I’ll open with a few remarks, then turn the discussion over to Peter Gaccione, Chief Executive Officer of American Shares. Our CFO, Robert Hiatt, will then walk through the third quarter’s financials. After the prepared comments, we’ll open the line for your questions. American Shared posted another solid quarter: revenue increased 6.3% compared with the same period a year earlier, hitting $5.1 million in Q3; with direct costs held tightly in check, gross margin improved 7.4% to $2.1 million. Throughout the third quarter, we continued investing heavily in new business initiatives and recorded net income of $118,000, or $0.02 per diluted share. That result reflected $128,000 of net interest expense, a sizable decline from last year, and one that our growing cash balances are increasingly offsetting through interest income. We’ve also engaged a compensation consulting firm to review our approach to compensation. As the quarter ended, cash balances totaled $14.7 million, or about $229 per share. Even during the pandemic, AMS consistently generated positive cash flow. During the quarter, our sales and marketing team continued generating and chasing a large volume of new business opportunities. We’re especially excited about three separate opportunities that we first discussed on our prior call. In the third quarter, we invested roughly $320,000 to advance those three separate opportunities. Without those expenses, net income would have been about $240,000 higher. In addition, we spent approximately $250,000 on these projects during the second quarter. Combined, that equals $570,000 invested so far this year. We look forward to sharing more details about these separate projects, which will expand our domestic footprint, when the timing is appropriate. Internationally, installation of new equipment with expanded treatment capabilities at two of our sites has proceeded smoothly. At our newest Cancer Center joint venture, in Puebla, Mexico, work is well underway to install the digital linear accelerator with VMAT, IGRT and radiosurgerbility for Linac. Once patient treatments start in early 2024, this will establish a new revenue stream for us, and it will be the most advanced radiation therapy treatment system in our catchment area. At our center in Ecuador, the upgraded Gamma Knife ICON is fully installed, and patient treatments are expected to resume this month; within Ecuador, it will be the only Gamma Knife for noninvasive radio surgery. I’m happy to report that when these installations are complete, AMS will have the most advanced radiation cancer treatment system in their region. Cancer patients in those locations need these advanced treatments, and we’re eager to serve them. To close, I hope I’ve conveyed some of the enthusiasm that all of us at AMS feel. There's a lot more detail I'd love to share with you, because it would give you a better picture of what we're developing. That said, I'm not at liberty to say it — we're looking for an unusual payoff on the $570,000 we've put in. Our leadership team and the Board see generating the best returns achievable as a fundamental fiduciary responsibility, and we continually weigh what potential investments could bring in against other options for using our cash. That's our job. Given the decisions we've taken and the potential of what's in the pipeline right now, I feel very confident — and on that note, Peter, I'll turn it over to you. Peter? Oh, and one more figure: roughly $2.29 per share.
Peter Gaccione
executiveThanks, Ray, and good afternoon to all of you. Our sales pipeline kept expanding through the third quarter. We credit that expansion to our sales force, which has found its rhythm, along with broader financial solutions and tighter coordination with our strategic OEM partners on specific prospects. As Ray mentioned, a number of important projects are working their way through the required sales process, and we hope to share news about them when the timing is right. On top of that, during the third quarter we secured 2 additional lease extensions with customers we already serve, marking our third and fourth new orders of this year. Both of these involve equipment upgrades to the Leksell Gamma Knife Espirit, the newest version, and once those installations wrap up early in Q1, they will rank among the first 10 in the U.S.; we are also pursuing several other new business possibilities, as well as working with current customers on extending existing agreements and upgrading products to more recent cancer treatment technology. Additionally, in the third quarter, AMS took part as an exhibitor for the very first time at the yearly ASTRO, which stands for the American Society of Radiation Therapy and Oncology Conference, the biggest radiation oncology society globally. Our team was fully present at the booth, and it gave us a wonderful chance to connect with customers, partners and OEMs. While at the conference, we moved several new business opportunities forward and strengthened both the breadth and depth of our relationships. We have shown up at other trade shows this year too, including the American Association of Neurosurgical Society, referred to as the AA&S, the Congress of Neurological Surgeons, referred to as the CNS, the Proton Therapy Cooperative Group, PTCOG, and the Peru Radiotherapy Congress; we also went to 3 conferences in Ecuador this year, where we have built excellent referral sources. Among these are the seventh Congress of International neurology, held in March, the Women in dentistry conference in May, and the Expo Dental Conference in September. Not long ago, we introduced a new dedicated website for GKF, the financing subsidiary of AMS. This fresh site gives neuroscience and radiosurgery professionals access to inventive financing options for acquiring a new Gamma Knife Espirit, along with other services. Our in-house customer advocate has proven to be a fantastic addition. He has not only helped lock in the 3 agreement extensions with existing customers that we have announced this year. He has also kept helping to raise the activity levels at our Gamma Knife sites. During the third quarter, Gamma Knife procedures rose roughly 8% period-over-period, following utilization improvements in the second quarter as well; to wrap up, we have generated solid momentum both internationally and in the U.S., and AMS holds a full pipeline of opportunities and is backed by a strong financial position. I will now hand the call over to Bob for a financial overview.
Bob Hiatt
executiveThanks, Peter, and good afternoon to all of you. For Q3, our top line rose 6.3%, hitting $5.1 million, versus $4.8 million during the comparable quarter a year earlier. U.S. sales made up $4.1 million, which was up 1.1%, while revenue from outside the country came to $1 million, compared with $727,000 in the prior year — a 35.9% increase. During Q3, the Florida proton therapy system brought in $2.2 million, down 5.9%, mostly because of a reduced number of fractions, which was partially offset by higher average reimbursement. Fraction volume for proton therapy in the quarter totaled 1,188, a drop of 12.8%, or 175 fewer fractions. That aligns with the normal quarter-to-quarter variability we experience. Gamma Knife revenue as a whole rose 9.9%, coming to $2.7 million. The gain was attributable to a greater number of procedures performed plus a modest bump in average reimbursement. Total Gamma Knife procedures in the third quarter were 316, up from 293 in the same quarter last year — an increase of 7.8%, or 23 procedures, which likewise sits within the customary range of quarterly fluctuation. Gross margin for the third quarter of 2023 grew 7.4% to $2.1 million, equal to 40.9% of revenue, compared with gross margin of $2 million, or 40.5% of revenue, in last year's third quarter. Selling and administrative costs in Q3 2023 climbed 37.7% to $1.7 million, from $1.3 million in the comparable period a year ago. Included in that figure is roughly $320,000 directed toward pursuing new business opportunities, as Ray noted, together with greater sales and marketing spending. Net interest expense for the 2023 period was $128,000, lower than the $216,000 recorded in last year's third quarter. That decrease stems from a higher rate on the company's variable rate debt, which was offset by additional interest income from the company's expanding cash balance. Operating income for the third quarter of 2023 was $90,000, compared with $448,000 of operating income in the third quarter of 2022, a shift caused by the bigger selling and administrative and interest expenses. Our income tax expense for Q3 was $60,000, whereas a year earlier in the same quarter it was $176,000. That decline chiefly reflected weaker earnings, adjustments related to a return-to-provision from foreign tax filings, and permanent differences in domestic taxes. American Shared Hospital Services posted net income attributable to the company of $118,000, or $0.02 per diluted share, for the third quarter of 2023; that compares with $316,000, or $0.05 per diluted share, for the third quarter of 2022. The decrease was mostly due to greater interest expense along with higher selling and administrative expense connected to supporting the company's new business opportunities. As Ray mentioned, we deployed roughly $320,000 during the third quarter to advance those new business opportunities. Without those costs, our bottom line would have been about $240,000 higher. For Q3 2023, fully diluted weighted average common shares outstanding were 6.4 million, while the same measure for Q3 2022 was 6.3 million. Book value per outstanding share stood at $3.50 at December 31, 2022, and reached $3.53 per outstanding share by quarter end. On a non-GAAP basis, adjusted EBITDA came in at $1.7 million for this period, which is lower than the $2 million we recorded in 2022's third quarter. As of September 30, 2023, our cash, cash equivalents and restricted cash totaled $14.7 million, compared with $12.5 million on December 31, 2022. Shareholders' equity at the close of the quarter, excluding noncontrolling interest in subsidiaries, stood at $22.1 million, or $3.33 per outstanding share, compared with $21.6 million, or $3.30 per outstanding share, at December 31, 2022. That said, $3.50 per outstanding share at December 31, 2022 and $3.53 per outstanding share at quarter end. That wraps up the formal part of what we have to present. Thank you for being with us today. We look forward to updating you on how we're doing in the quarters ahead. Jason, we'd now like to give the call back to you and open up the lines for questions.
Tony Kamin
analystRay, as you’re aware, for a great many years I’ve been a shareholder who’s been extremely supportive and appreciative of management. That said, at this juncture, 5 points really stand out to me. Right now the stock trades 40% below book value. Each share currently changes hands for less than the cash attributable to each share. Since merely the previous conference call, the stock has fallen 15%. It sits 35% beneath its year high. And across 17 years, the shares have moved within a narrow band. I noticed your remark that a compensation committee was being hired. In my view, it’s truly time for the Board to give far more serious thought to shareholders in a manner different from what has been done previously. I’d press you all to devote considerably more consideration and considerably more responsibility to that. My proposals are really 2: first, that the company undertake a $2 million share buyback. As you said, you anticipate big things from the investments being made. Wouldn’t now be the correct moment to buy back stock beneath cash value and so far beneath book value that doing so would be accretive? I realize that previously you’ve stated you don’t wish to spend the cash. Should that be so, the second option I’d put forward is a 10% stock dividend that turns into a sort of regular stock dividend until you believe you can either pay a cash dividend or head toward or shift toward repurchasing shares. In any case, so my question is, once more, if you’re obtaining a compensation committee presumably to compensate management and the Board, I feel that given really decades of dismal stock performance, while the company performs quite well on a lot of metrics, it’s truly time for the Board, in my opinion, to give thought to the shareholders and to what you can do about the chronic gap in the value of the company, which I know you believe, based on many statements, is extremely undervalued.
Ray Stachowiak
executiveYes. Tony, thanks for joining us again here today; we take our responsibilities to our shareholders very seriously. And we’re always looking at the capital we do have available, our cash balances and the lines of credit we have available and we’re also comparing it to the steadily increasing pipeline of activities that we have. And our formula is, what’s the greatest expected return to our shareholders; and we are in a very capital-intensive industry. And our business order intake, our pipeline has been growing and our order intake is slowly increasing our rate of orders that we’re taking in is increasing. And we’re constantly evaluating our capital position and the capital that would be required for these projects. As far as our stock price, I think as I’ve often mentioned, I really believe our stock is undervalued. It’s very thinly traded. We are looking at taking certain steps aimed at boosting activity levels; and I believe the recent drop in our stock price stems from the market misreading a few of our recent items, especially, say, the second quarter, when we posted a loss, and we had a few blips during that second quarter. There was what I'd call an isolated sort of exception, an expense of, I believe, $578,000 during the second quarter, a onetime item, more or less. On top of that, there was the additional $250,000 that we invested; this quarter, we posted a profit. And our profit would have come in higher if we hadn't put the $320,000 into these unique business opportunities. Tony, I simply wish I were able to disclose or share in greater detail what I see headed our way. I wish I could do that; but as a public company, I'm not permitted to. So the only thing I can tell you is stay in touch, our stock is undervalued. I believe our performance has remained steady. We are a profitable company. We are growing, and our growth will be more incremental. Going forward, with the pipeline we have built and the order intake we anticipate getting and the capital deployment we anticipate taking place.
Tony Kamin
analystSo, Ray, like I said, I get why you'd want to hold onto cash. Another option, and it would barely cost you anything beyond a few small administrative charges, is paying stock dividends on a regular basis. What I believe that accomplishes is giving shareholders an incentive to stay invested long term and keep their shares, since they'd receive that dividend annually. And this company doesn't exactly have a huge number of shares outstanding at the moment. So my honest view is that your Board ought to look into it. If you went with something like a regular stock dividend at a 10% level, my sense is it would benefit your shareholders. And on that note, I'd appreciate it if you could speak to that as my follow-up, if you don't mind.
Ray Stachowiak
executiveAll right. I've made note of it, Tony. Thanks for your input.
Analyst
analystNice results this quarter, folks. Turning to what lies ahead, my own vote would be against handing out cash through dividends or buybacks. In my view, doing so would suggest your expansion prospects weren't as strong as they perhaps could be. That's simply one more perspective on the opposite side of the debate. What I'd like to ask about is the $550,000 you've put into the process. Where exactly does that money go? Does it cover internal salaries? Legal bills, site visits, signing leases? Could you give us some sense of how those expenses broke down across those investments?
Ray Stachowiak
executiveThanks for that question, Michael. We appreciate you joining us today and appreciate your time. The funds we've deployed — the 570,000 split across the second and third quarter — went toward 3 distinct business opportunities, and they carried a great deal of upfront costs required to work through the process of securing the deal, so to speak. Legal fees have been part of it. There have also been expenses tied to the regulatory filings that must be made in order to acquire the business, plus other consultants and advisers who, in our view, have been quite helpful in strengthening our capacity to get these opportunities across the finish line. That's likely as much as I'm able to share, Michael, in response to what you asked. What I can say is that I've spent a few decades now as an entrepreneur and investor, and that money wouldn't have been spent if these opportunities weren't worth pursuing.
Ray Stachowiak
executiveThanks, Jason, and I appreciate all of you taking the time to be with us today. In my view, American shares have truly never been better positioned, given the pipeline opportunities in front of us, our financial standing, and the capital that's ready to be put to work. That future has us excited. So, as I said earlier, please keep watching. We'll talk with you again on our 2023 year-end call in March; in the meantime, don't wait — reach out to us directly whenever you like if anything comes up before then. Take care, and enjoy the rest of your evening. Goodbye.
Operator
operatorThat brings an end to our call. We appreciate your participation in today's presentation. You are free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.